激素受体阳性乳腺癌常用复发风险预测工具研究现状  

Research status of common recurrence risk prediction tools for hormone receptor-positive breast cancer

作　　者：张莉华 盛美红[1] ZHANG Lihua;SHENG Meihong(Department of Imaging,Nantong First People’s Hospital,Nantong 226001,Jiangsu,China)

机构地区：[1]南通市第一人民医院影像科,南通226001

出　　处：《中国临床医学》2024年第3期499-507,共9页Chinese Journal of Clinical Medicine

基　　金：江苏省妇幼健康科研项目(F202037)。

摘　　要：乳腺癌是危害全球女性健康的恶性肿瘤之一,激素受体(hormone receptor,HR)阳性是其最常见的分子亚型。乳腺癌的异质性导致患者术后复发风险各异,因此需要高灵敏度的风险预测工具帮助临床医生评估不同患者的预后,制定个性化治疗方案。目前使用较为广泛的HR阳性乳腺癌患者术后复发风险预测工具是基于多基因检测和临床病理因素开发的预后模型,例如Oncotype DX检测、4项免疫组化评分等。此外,基于影像特征建立的预后评估模型也逐渐应用于临床。在临床实践中,依据风险评估模型可较为准确地评估乳腺癌患者术后复发风险和预后,指导患者的个体化临床诊疗方案,以改善患者生存质量,延长总生存期。Breast cancer is one of the malignant tumors that seriously threaten the health of women worldwide,with hormone receptor(HR)positivity being its most common molecular subtype.The heterogeneity of breast cancer leads to varying risks of recurrence after surgery for patients,thus requiring highly sensitive recurrence risk prediction tools to help clinical doctors assess patients’prognoses and to develop personalized treatment plans.Currently,widely used recurrence risk prediction tools developed based on multi-gene testing or clinical pathological factors for HR-positive breast cancer patients after surgery,such as Oncotype DX,IHC 4 scores.In addition,prognostic models based on imaging features are also gradually being applied in clinical practice.The recurrence risk prediction tools can more accurately assess the risk of recurrence and prognosis of breast cancer patients after surgery,guide individualized clinical diagnosis and treatment plans for patients,improve the quality of life of patients,and prolong overall survival.

关 键 词：乳腺癌 HR阳性 复发风险 预后 预测模型 

分 类 号：R737.9[医药卫生—肿瘤]